Meeting report of the second European biotransformation workshop
Challenges and opportunities in the field of biotransformation were presented and discussed at the 2nd European Biotransformation workshop which was conducted virtually in collaboration with the DMDG on November 24/25, 2021. Here we summarise the presentations and discussions from this workshop.The following topics were covered:Regulatory requirements and biotransformation studies for antibody drug conjugates (ADCs) and antisense oligonucleotides (ASOs).Solutions for mass spectral data processing of peptides and oligonucleotides.Future outsourcing needs in biotransformation for new modalities.Established quantitative and qualitative workflows for metabolite identification.New in vitro systems to study new chemical entities (NCEs) with low metabolic turnover.New strategies on the timing of the human ADME (absorption, distribution, metabolism, excretion) study and to investigate the impact of human microbiome on drug development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Xenobiotica; the fate of foreign compounds in biological systems - 52(2022), 4 vom: 17. Apr., Seite 426-431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walles, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.06.2022 Date Revised 23.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/00498254.2022.2064253 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339401761 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339401761 | ||
| 003 | DE-627 | ||
| 005 | 20231226002820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00498254.2022.2064253 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339401761 | ||
| 035 | |a (NLM)35410573 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walles, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Meeting report of the second European biotransformation workshop |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2022 | ||
| 500 | |a Date Revised 23.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Challenges and opportunities in the field of biotransformation were presented and discussed at the 2nd European Biotransformation workshop which was conducted virtually in collaboration with the DMDG on November 24/25, 2021. Here we summarise the presentations and discussions from this workshop.The following topics were covered:Regulatory requirements and biotransformation studies for antibody drug conjugates (ADCs) and antisense oligonucleotides (ASOs).Solutions for mass spectral data processing of peptides and oligonucleotides.Future outsourcing needs in biotransformation for new modalities.Established quantitative and qualitative workflows for metabolite identification.New in vitro systems to study new chemical entities (NCEs) with low metabolic turnover.New strategies on the timing of the human ADME (absorption, distribution, metabolism, excretion) study and to investigate the impact of human microbiome on drug development | ||
| 650 | 4 | |a Congress | |
| 650 | 4 | |a Biotransformation of new modalities | |
| 650 | 4 | |a antibody drug conjugates | |
| 650 | 4 | |a antisense oligonucleotides | |
| 650 | 4 | |a human ADME | |
| 650 | 4 | |a metabolite quantitation and qualification | |
| 650 | 4 | |a microbiome | |
| 650 | 4 | |a microphysiological systems | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Pähler, A |e verfasserin |4 aut | |
| 700 | 1 | |a Isin, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Weidolf, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Xenobiotica; the fate of foreign compounds in biological systems |d 1971 |g 52(2022), 4 vom: 17. Apr., Seite 426-431 |w (DE-627)NLM000064742 |x 1366-5928 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2022 |g number:4 |g day:17 |g month:04 |g pages:426-431 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00498254.2022.2064253 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2022 |e 4 |b 17 |c 04 |h 426-431 | ||